Hansa Biopharma sees 2025 growth through expanded IDEFIRIX adoption and new market reimbursements
Source: SeekingAlpha
2025-02-06 13:13:33 ET
More on Hansa Biopharma
- Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript
- Historical earnings data for Hansa Biopharma
- Financial information for Hansa Biopharma
Read the full article on Seeking Alpha
For further details see:
Hansa Biopharma sees 2025 growth through expanded IDEFIRIX adoption and new market reimbursements
Hansa Biopharma AB
NASDAQ: HNSBF
HNSBF Trading
-85.0% G/L:
$2.91 Last:
28,750 Volume:
$2.91 Open:
HNSBF Latest News
September 24, 2025 02:06:00 pm
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
